Imaging for early stage breast cancer

First page Table of contents Previous page 916 Next page Last page

Risk factors: after lumpect. + WBRT +/- boost

Fig 4. 10-year OS & DFS, specified for trastuzumab use in luminal B/HER2.

Van Maaren M et al. Int J Cancer 2018, doi: 10.1002/ijc.31914.

Made with FlippingBook - Online magazine maker